Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breakthrough-Style Program For ANDAs Added To House User Fee Bill

Executive Summary

Energy and Commerce subcommittee unanimously advances reauthorization legislation with four added amendments, including one that would allow for certain generic sponsors to meet early and often with FDA to speed development.

Advertisement

Related Content

Drug Pricing Reform In US: It’s Over For 2017
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
Unapproved Uses Bill May Eventually Pass, But Would Likely Need Additional Safeguards
Generic Combination Products May Be Permitted Delivery Device Variations
Generic Priority Review Expanded In Senate User Fee Bill
US FDA Gains Budget Increase In FY 2017… And Not Through Fees
REMS Could Block ANDAs With 'Legitimate Business Justification' In Senate Bill
US Generic 'Breakthrough' Pathway Could Have Unintended Consequences
Trump's Budget Outline Threatens User Fee Agreements
Complex ANDAs To Be Allowed Pre-Submission Product Meetings

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel